 Connection
Lisa Abuogi to HIV Integrase Inhibitors
This is a "connection" page, showing publications Lisa Abuogi has written about HIV Integrase Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.443 |
|
|
|
-
Beck IA, Boyce CL, Bishop MD, Oldroyd AR, du Toit L, Saimen A, Ramarope KM, Hitchcock S, du Plessis NM, Mbogo L, Chohan BH, Maheria P, Oyaro P, Knowles K, Zhang Z, Brummel SS, Drain PK, Smith RA, Gottlieb GS, Abuogi L, Patel RC, Farquhar C, Wiznia A, Ruel TD, Rossouw TM, Hawes SE, Frenkel LM. HIV Resistance to Dolutegravir Varies With Coadministered Agents. Clin Infect Dis. 2026 Apr 30; 82(4):592-596.
Score: 0.223
-
Ombajo LA, Nkuranga J, Penner J, Kamau EW, Ismael N, Munseri P, Ayakaka I, Labhardt N, Wamalwa D, Ramgi P, Chissumba RM, Wagude J, Bakari M, Omodi V, Otieno E, Abuogi L, Patel R, Opondo C, Grint D, King'wara L, Macharia A, Mulwa A, Amoth P. The dolutegravir failure cohort: A multi-country longitudinal cohort with a randomised clinical trial of continued dolutegravir versus switch to darunavir in people with viraemia while on dolutegravir in Sub-Saharan Africa (The Ndovu Study) protocol. PLoS One. 2026; 21(3):e0330792.
Score: 0.221
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|